Considering all (40 = 16+24) patients with ovarian cancer, applying a two-step algorithm enabled detection of 40% (16/40) more patients with BRCA1/2 mutations potentially benefiting from PARP inhibitor therapy. Here, BRCA1 is linked to ovarian carcinoma.